Freeze-Dried Platelet Product for the Treatment of Trauma-Associated Blood Loss in Canines

The Defense Health Agency (DHA) is conducting market research to identify technologies that meet requirements for the development of a freeze-dried platelet product for the treatment of trauma-associated blood loss in canines. The product should have desired characteristics such as being safe, efficacious, and shelf-stable, with a minimum shelf life of one year. The product should also be easy to administer and maintain efficacy and stability during storage at ambient temperature. • The product should provide a safe, efficacious, and shelf-stable canine platelet treatment that is easy to administer. • The product should maintain efficacy and stability during storage at ambient temperature for at least one year. • The product should have evidence of safety and efficacy as compared to fresh platelet concentrate. • The product should have a reconstitution time and temperature that is suitable for use in austere environments. • The product should have a shelf-life stability that is suitable for use in austere environments. • The product should have a size and weight that is suitable for use in austere environments. • The product should have FDA (CVM) regulatory status that is suitable for use in austere environments.